INSMED INC

INSMED’s Form 144 details a 25,000‑share secondary sale, offering modest liquidity while its kinase‑inhibitor and orphan‑drug pipeline shows strong early clinical promise and FDA fast‑track status.

Japanese approval of BRINSUPRI gives patients with non‑CF bronchiectasis a once‑daily oral therapy that reduces exacerbations, slows lung decline, and preserves immune function.

Insmed Inc. boosts Q2 2026 earnings, upgrades Brinsupri and TPIP revenue outlooks, citing strong sales, Phase 3 success, and FDA progress.

Insmed’s Q2 2026 earnings beat expectations thanks to Brinsupri’s strong sales, and its clinical data shows robust PAH benefits and promising TPIP results, boosting future growth forecasts.

Insmed’s BRINSUPRI breakthrough: 30%+ 6‑minute walk improvement, FDA accelerated approval, $7B peak sales, and robust insider confidence—all driving PAH market growth.

Insmed’s treprostinil palmitil inhalation powder shows sustained efficacy and safety, but faces regulatory, reimbursement, and competitive hurdles—key insights for PAH investors.

Insmed’s once‑daily treprostinil palmitil inhalation powder shows 12‑month PAH benefits, strong safety, and a $24‑$28k price point, positioning it to win market access, outpace rivals, and secure a $500M+ launch before the 2029 patent cliff.

Insmed’s June 2026 update reveals insider‑trade compliance and a major European trial of brensocatib for bronchiectasis, aiming to transform treatment and guide future approvals.

Insmed’s S&P 500 debut boosts liquidity and visibility, but shares moved modestly amid steady markets, commodity support, and cautious monetary policy.

Explore how Baker Bros. Advisors’ stake in BeOne Medicines could boost specialty‑drug pipeline, regulatory speed, and device‑therapy integration.